Fri, 20 May 2022

Prevalence of various types of cancers such as breast, prostate, and lung cancer, development of biological & targeted drug therapies, and reliability of cancer biomarkers fuel the growth of the global cancer biomarkers market. On the other hand, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations & reimbursement policies impede the growth to some extent. However, high-end technological advancements are expected to create multiple opportunities in the industry.

The global cancer biomarkers market size is expected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027, in terms of value. Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics,Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027.

Download Sample Report with Detailed COVID-19 Impact Analysis at:

https://www.alliedmarketresearch.com/request-sample/1443

COVID-19 scenario-

  • Prevention of cancer by analyzing various cancer biomarkers using different diagnostic methods is an effective approach to obtain quick results for the treatment.So, although a number of industries have been badly affected by the pandemic, the medical diagnostics industry has, quite naturally, not confronted the impacts on a severe note.
  • However, the global lockdown has led to postponement of the procedures and accordingly, there's been a short-term decline in the revenue rate in cancer biomarkers market. But, it's expected that the market would experience massive gains through the end of the pandemic.

Key Findings of the Study

  • By profiling technologies, the omic technologies segment accounted for the highest market share of 54% in 2019, and is anticipated to grow at the fastest rate during the forecast period.
  • By region, North America was the major shareholder and accounted for the highest share of 36% in 2019.
  • Based on cancer type, the breast cancer segment is expected to grow at a CAGR of 16.7% during the forecast period.
  • On the basis of biomolecules, the genetic biomarkers segment dominated the market in 2019 and is anticipated to maintain its dominance during the forecast period.

The genetic biomarkers segment to dominate during the estimated period-

Based on biomolecule, the genetic biomarkers segment contributed to nearly half of the global cancer biomarkers market revenue in 2019, and is anticipated to lead the trail till 2027. This is due to its accuracy and precision while detecting cancer and monitoring the effectiveness of the treatment. Simultaneously, the glycol-biomarkers segment would portray the fastest CAGR of 12.5% by 2027. Increase in awareness about the roles of glycosylation and other post translational modifications in cancer biology fuels the segment growth.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1443

North America to dominate in terms of revenue-

Based on geography, North America held the major share, garnering more than one-third of the global cancer biomarkers market, owing to strong focus on innovation and technological advancements in healthcare & diagnostics in the region. At the same time, Asia-Pacific is expected to manifest the fastest CAGR of 15.1% from 2020 to 2027. This is due to increase in prevalence of cancer, rise in patient awareness, and increase in disposable incomes in the province.

Frontrunners in the industry-

  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bristol-Myers Squibb Company
  • Exact Sciences Corporation
  • F.Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Qiagen N.V.
  • Merck KGaA
  • PerkinElmer, Inc.
  • Siemens AG

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with vario research data tables and confirms utmost accuracy in our market forecasting. Each and ever us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Tags:

See Campaign: https://www.alliedmarketresearch.com/cancer-biomarkers-market

Contact Information:

David Correa

5933 NE Win Sivers Drive

#205, Portland, OR 97220

United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Tags:Reportedtimes, Financial Content, PR-Wirein, iCN Internal Distribution, Research Newswire, English

More California News

Access More

Sign up for California State News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!